BOLDEN THERAPEUTICS RECEIVES $497,500 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS
CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.